CA2812362A1 - Matrix metalloproteinase inhibitors - Google Patents
Matrix metalloproteinase inhibitors Download PDFInfo
- Publication number
- CA2812362A1 CA2812362A1 CA2812362A CA2812362A CA2812362A1 CA 2812362 A1 CA2812362 A1 CA 2812362A1 CA 2812362 A CA2812362 A CA 2812362A CA 2812362 A CA2812362 A CA 2812362A CA 2812362 A1 CA2812362 A1 CA 2812362A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- amino
- methylsulfonyl
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/04—1,2,3-Triazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2279/DEL/2010 | 2010-09-24 | ||
IN2279DE2010 | 2010-09-24 | ||
PCT/IB2011/054229 WO2012038944A1 (en) | 2010-09-24 | 2011-09-26 | Matrix metalloproteinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2812362A1 true CA2812362A1 (en) | 2012-03-29 |
Family
ID=44903306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2812362A Abandoned CA2812362A1 (en) | 2010-09-24 | 2011-09-26 | Matrix metalloproteinase inhibitors |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2619179A1 (ja) |
JP (1) | JP2013538821A (ja) |
KR (1) | KR20140045287A (ja) |
CN (1) | CN103249719A (ja) |
AU (1) | AU2011306398A1 (ja) |
BR (1) | BR112013008008A2 (ja) |
CA (1) | CA2812362A1 (ja) |
MX (1) | MX2013003362A (ja) |
SG (1) | SG188641A1 (ja) |
WO (1) | WO2012038944A1 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6360040B2 (ja) | 2012-05-03 | 2018-07-18 | カラ ファーマシューティカルズ インコーポレイテッド | 粘液浸透性被覆粒子、組成物、医薬組成物、医薬製剤、及びそれらの形成方法 |
US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
WO2013166385A1 (en) | 2012-05-03 | 2013-11-07 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
EP2956138B1 (en) | 2013-02-15 | 2022-06-22 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
AU2014219024B2 (en) | 2013-02-20 | 2018-04-05 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
CN108530458A (zh) | 2013-11-01 | 2018-09-14 | 卡拉制药公司 | 治疗化合物的结晶形式及其用途 |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10336767B2 (en) | 2016-09-08 | 2019-07-02 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
WO2018048747A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CA3036340A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2022222472A1 (en) | 2021-02-19 | 2023-09-28 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU690703B2 (en) | 1994-06-22 | 1998-04-30 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
US5863915A (en) * | 1996-05-15 | 1999-01-26 | Bayer Corporation | Substituted 4-arylbutyric acid derivatives as matrix metalloprotease |
EP1100792B1 (en) | 1998-07-30 | 2004-03-17 | Warner-Lambert Company LLC | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
US6366675B1 (en) | 1999-05-21 | 2002-04-02 | Kohji Toda | Sound pressure detecting system |
GB0314488D0 (en) | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
-
2011
- 2011-09-26 EP EP11776885.3A patent/EP2619179A1/en not_active Withdrawn
- 2011-09-26 KR KR1020137010369A patent/KR20140045287A/ko not_active Application Discontinuation
- 2011-09-26 WO PCT/IB2011/054229 patent/WO2012038944A1/en active Application Filing
- 2011-09-26 SG SG2013021654A patent/SG188641A1/en unknown
- 2011-09-26 AU AU2011306398A patent/AU2011306398A1/en not_active Abandoned
- 2011-09-26 JP JP2013529763A patent/JP2013538821A/ja not_active Withdrawn
- 2011-09-26 CA CA2812362A patent/CA2812362A1/en not_active Abandoned
- 2011-09-26 BR BR112013008008A patent/BR112013008008A2/pt not_active Application Discontinuation
- 2011-09-26 MX MX2013003362A patent/MX2013003362A/es unknown
- 2011-09-26 CN CN2011800564244A patent/CN103249719A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2619179A1 (en) | 2013-07-31 |
SG188641A1 (en) | 2013-04-30 |
WO2012038944A1 (en) | 2012-03-29 |
JP2013538821A (ja) | 2013-10-17 |
MX2013003362A (es) | 2013-06-05 |
CN103249719A (zh) | 2013-08-14 |
AU2011306398A1 (en) | 2013-05-02 |
BR112013008008A2 (pt) | 2016-06-21 |
KR20140045287A (ko) | 2014-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2812362A1 (en) | Matrix metalloproteinase inhibitors | |
KR20130137174A (ko) | 기질 메탈로프로테나제 저해제 | |
JP2013540754A (ja) | マトリックスメタロプロテイナーゼ阻害剤 | |
US7645784B2 (en) | Benzimidazole derivatives | |
SG187654A1 (en) | Matrix metalloproteinase inhibitors | |
EP1856063B1 (en) | 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases | |
EP1147095B1 (en) | 2, 3, 4, 5-tetrahydro-1h-[1, 4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors | |
JP2003206273A (ja) | 分枝アミノ酸依存性アミノトランスフェラーゼ阻害剤及び神経変性疾病におけるそれらの使用 | |
PL198827B1 (pl) | ω-Amidy N-arylosulfonyloaminokwasów, sposób ich wytwarzania, środek farmaceutyczny i zastosowanie ω-amidów N-arylosulfonyloaminokwasów | |
JP2002501056A (ja) | マトリクス金属プロテイナーゼ阻害薬としての2,3,4,5−テトラヒドロ−1h−[1,4]−ベンゾジアゼピン−3−ヒドロキサム酸 | |
JP4209659B2 (ja) | アミジノ誘導体並びにそれを用いた抗血液凝固剤および血栓症治療剤 | |
JP2003524000A (ja) | オルト−スルホンアミドアリールヒドロキサム酸、それらの製造方法およびマトリックスメタロプロテイナーゼ阻害薬としてのそれらの使用 | |
RAUF et al. | International Bureau |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20130322 |
|
FZDE | Discontinued |
Effective date: 20140926 |